Aptus Capital Advisors Boosts Gilead Sciences Stake

Investment firm increases position in biopharmaceutical company by over 240%

Published on Mar. 7, 2026

Got story updates? Submit your updates here. ›

Aptus Capital Advisors LLC grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 241.8% in the 3rd quarter, according to a recent SEC filing. The firm now owns 77,080 shares of the biopharmaceutical company's stock, up from 22,554 shares previously.

Why it matters

Gilead Sciences is a major player in the biopharmaceutical industry, known for its antiviral therapies for HIV and viral hepatitis. The significant increase in Aptus Capital's position suggests the investment firm sees strong potential in Gilead's business and future prospects.

The details

Aptus Capital Advisors added 54,526 shares of Gilead Sciences during the 3rd quarter, bringing its total holdings to 77,080 shares worth approximately $8.56 million. The firm's increased stake in Gilead comes as the company continues to expand its product portfolio beyond its core antiviral therapies, including into oncology and cell therapy.

  • Aptus Capital Advisors increased its Gilead Sciences stake in the 3rd quarter of 2026.

The players

Aptus Capital Advisors LLC

An investment management firm that grew its stake in Gilead Sciences by over 240% in the 3rd quarter of 2026.

Gilead Sciences, Inc.

A biopharmaceutical company focused on developing antiviral therapies, as well as expanding into oncology and cell therapy.

Got photos? Submit your photos here. ›

The takeaway

Aptus Capital's significant increase in its Gilead Sciences position suggests the investment firm sees strong potential in the biopharmaceutical company's future growth and diversification efforts beyond its core antiviral therapies.